This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2018 Jun;18(3):189-191.

doi: 10.1016/j.clbc.2017.09.009. Epub 2017 Sep 19.

Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment

Melina-Theoni Gyparaki¹, Athanasios G Papavassiliou²

Affiliations

Affiliations

¹ Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: papavas@med.uoa.gr.

PMID: 29042129
DOI: 10.1016/j.clbc.2017.09.009

Review

Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment

Melina-Theoni Gyparaki et al. Clin Breast Cancer. 2018 Jun.

. 2018 Jun;18(3):189-191.

doi: 10.1016/j.clbc.2017.09.009. Epub 2017 Sep 19.

Authors

Melina-Theoni Gyparaki¹, Athanasios G Papavassiliou²

Affiliations

¹ Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: papavas@med.uoa.gr.

PMID: 29042129
DOI: 10.1016/j.clbc.2017.09.009

No abstract available

PubMed Disclaimer

Similar articles

Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.
Curry E, Zeller C, Masrour N, Patten DK, Gallon J, Wilhelm-Benartzi CS, Ghaem-Maghami S, Bowtell DD, Brown R. Curry E, et al. Cancer Res. 2018 Mar 15;78(6):1383-1391. doi: 10.1158/0008-5472.CAN-17-1650. Epub 2018 Jan 16. Cancer Res. 2018. PMID: 29339543
Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA, Rodríguez-Antolín C, Vera O, Pernía O, Esteban-Rodríguez I, Dolores Diestro M, Benitez J, Sánchez-Cabo F, Alvarez R, De Castro J, Ibanez de Cáceres I. Soto JA, et al. Clin Epigenetics. 2021 Aug 28;13(1):167. doi: 10.1186/s13148-021-01149-8. Clin Epigenetics. 2021. PMID: 34454589 Free PMC article.
The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
Wambecke A, Ahmad M, Lambert B, Joly F, Poulain L, Denoyelle C, Meryet-Figuiere M. Wambecke A, et al. Gynecol Oncol. 2020 Mar;156(3):726-733. doi: 10.1016/j.ygyno.2019.12.020. Epub 2019 Dec 26. Gynecol Oncol. 2020. PMID: 31883617 Review.
Epigenetics: a way to understand the origin and biology of testicular germ cell tumors.
Okamoto K. Okamoto K. Int J Urol. 2012 Jun;19(6):504-11. doi: 10.1111/j.1442-2042.2012.02986.x. Epub 2012 Feb 29. Int J Urol. 2012. PMID: 22375557 Review.
Epigenetics and ovarian cancer.
Nephew KP, Balch C, Zhang S, Huang TH. Nephew KP, et al. Cancer Treat Res. 2009;149:131-46. doi: 10.1007/978-0-387-98094-2_6. Cancer Treat Res. 2009. PMID: 19763434 Review. No abstract available.

See all similar articles

Cited by

LncRNA-MSC-AS1 inhibits the ovarian cancer progression by targeting miR-425-5p.
Zhao Y, Yuan D, Zhu D, Xu T, Huang A, Jiang L, Liu C, Qian H, Bu X. Zhao Y, et al. J Ovarian Res. 2021 Aug 28;14(1):109. doi: 10.1186/s13048-021-00857-2. J Ovarian Res. 2021. PMID: 34454554 Free PMC article.
A Comparative Analysis of Genetic and Epigenetic Events of Breast and Ovarian Cancer Related to Tumorigenesis.
Longacre M, Snyder NA, Housman G, Leary M, Lapinska K, Heerboth S, Willbanks A, Sarkar S. Longacre M, et al. Int J Mol Sci. 2016 May 18;17(5):759. doi: 10.3390/ijms17050759. Int J Mol Sci. 2016. PMID: 27213343 Free PMC article. Review.
Exploring tumor microenvironment in molecular subtyping and prognostic signatures in ovarian cancer and identification of SH2D1A as a key regulator of ovarian cancer carcinogenesis.
Guo H, Zhang L, Su H, Yang J, Lei J, Li X, Zhang S, Zhang X. Guo H, et al. Heliyon. 2024 Sep 17;10(18):e38014. doi: 10.1016/j.heliyon.2024.e38014. eCollection 2024 Sep 30. Heliyon. 2024. PMID: 39347397 Free PMC article.
Creation and validation of models to predict response to primary treatment in serous ovarian cancer.
Gonzalez Bosquet J, Devor EJ, Newtson AM, Smith BJ, Bender DP, Goodheart MJ, McDonald ME, Braun TA, Thiel KW, Leslie KK. Gonzalez Bosquet J, et al. Sci Rep. 2021 Mar 16;11(1):5957. doi: 10.1038/s41598-021-85256-9. Sci Rep. 2021. PMID: 33727600 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information